Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) shares dropped 9.3% during mid-day trading on Friday . The company traded as low as C$0.98 and last traded at C$0.98. Approximately 103,958 shares changed hands during trading, a decline of 15% from the average daily volume of 123,015 shares. The stock had previously closed at C$1.08.
Analysts Set New Price Targets
Separately, Raymond James raised Oncolytics Biotech to a "moderate buy" rating in a research report on Thursday, November 14th.
Read Our Latest Stock Report on ONC
Oncolytics Biotech Stock Performance
The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The stock's 50 day moving average is C$1.12 and its two-hundred day moving average is C$1.31. The firm has a market cap of C$67.83 million, a P/E ratio of -2.45 and a beta of 1.35.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Stories
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
